使用Valsalva移植物行主动脉瓣再植入的二十年经验
该研究回顾了2000年2月至2021年12月连续265例接受Valsalva移植物主动脉瓣再植入的主动脉根部动脉瘤患者,平均随访85±63个月。15年总体生存率为87.6±3.4,无心脏死亡、无复发性AR≥3+及无再手术率均保持稳定。结论认为该技术长期结果优异,并随学习曲线逐渐改善。
要点
- 15年总体生存率87.6±3.4,无心脏死亡稳定在99.6±0.4。
- 10年和15年无复发性AR≥3+为92.2±2.1,无再手术为95.9±1.6。
- 感染性心内膜炎、血栓栓塞和出血发生率分别为0.8%、2.2%和2.0%。
核心结论
- 使用Valsalva移植物行主动脉瓣再植入的首个长期随访显示优异结果。
- 这些长期结果随学习曲线逐渐改善,并在观察的第二个十年保持稳定。
- 常规使用卡尺可能有助于进一步改善结果,但需更长期随访确认。
研究设计与样本
- 回顾性单中心连续病例系列,纳入2000年2月至2021年12月265例主动脉根部动脉瘤患者。
- 所有患者接受Valsalva移植物主动脉瓣再植入,自2018年起常规使用卡尺行瓣叶折叠。
- 平均随访85±63个月,随访包括临床评估和超声心动图。
主要发现
- 队列中位年龄55±18岁,男性占87.2%,二叶主动脉瓣占18.9%,Marfan综合征占10.6%,55.9%有主动脉瓣反流≥2+。
- 15年总体生存率为87.6±3.4,无心脏死亡在5、10、15年稳定在99.6±0.4。
- 10年和15年无复发性AR≥3+为92.2±2.1,无再手术为95.9±1.6。
- 感染性心内膜炎发生率为0.8%,血栓栓塞为2.2%,出血为2.0%。
- 7例需再手术患者中6例发生在早期经验阶段(最后一例在2004年)。
关键数值与推荐
- 15年总体生存率87.6±3.4。
- 无心脏死亡在5、10、15年稳定在99.6±0.4。
- 10年和15年无复发性AR≥3+为92.2±2.1,无再手术为95.9±1.6。
- 感染性心内膜炎0.8%,血栓栓塞2.2%,出血2.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 早期次优结果对残余主动脉瓣反流有负面影响。
- 常规使用卡尺可能有助于进一步改善结果,但这些数据需更长期随访确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Over the past 20 years, valve-sparing aortic root replacement has aroused increasing interest because of a progressive attitude towards the preservation of natural tissue. Aortic reimplantation is the most used technique to spare the valve, allowing simultaneously aortic root replacement and aortic annular stabilization. The reimplantation into a graft with sinuses guarantees an optimal anatomic and functional reconstruction with established good results at 15 years. The aim of this study is to report the world longest follow-up (up to 20 years) of aortic valve reimplantation using the Valsalva graft. METHODS: From February 2000 to December 2021, 265 consecutive patients with aortic root aneurysm received aortic valve reimplantation using the Valsalva graft. From 2018, leaflet plication with the routine use of calliper was performed. For each patient, we performed both intraoperative and post-procedural transoesophageal echocardiography. All patients were followed with clinical assessment and echocardiography. The mean duration of follow-up was 85 ± 63 months. RESULTS: The study cohort had a median age of 55 ± 18 and 87.2% were male. The aortic root aneurysm was associated to bicuspid aortic valve in 18.9% of patients and to Marfan syndrome in 10.6% of cases. 55.9% had an aortic regurgitation ≥ 2+. Overall survival at 15 was 87.6 ± 3.4. Freedom from cardiac death was stable at 99.6 ± 0.4 at 5, 10 and 15 years. Freedom from recurrent AR ≥3+ and freedom from reoperation remained stable at 10 and 15 years at 92.2 ± 2.1 and 95.9 ± 1.6, respectively. There was a minimal incidence of infective endocarditis (0.8%), thromboembolism (2.2%) and haemorrhage (2.0%). Six out of 7 patients requiring reoperation had surgery in the first period of our experience (last in 2004). Early suboptimal results had a negative effect on residual aortic regurgitation. Moreover, we hypothesized that the routine use of calliper may have contributed to a further improvement of the outcome, even if these data need to be confirmed by a longer follow-up. CONCLUSIONS: The first long-term follow-up after aortic valve reimplantation using the Valsalva graft demonstrated excellent results. These long-term results gradually improved with learning curve, remaining stable during the second decade of observation. The systematic use of calliper may have contributed to a further improvement of the outcome.
引用
- Chirichilli I, Scaffa R, Irace FG, et al. Twenty-year experience of aortic valve reimplantation using the Valsalva graft. Eur J Cardiothorac Surg. 2023. PMID: 36579861. doi:10.1093/ejcts/ezac591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。